{"id":"open-label-glimepiride","safety":{"commonSideEffects":[{"rate":"5–15","effect":"Hypoglycemia"},{"rate":"2–5","effect":"Weight gain"},{"rate":"1–3","effect":"Dizziness"},{"rate":"1–3","effect":"Headache"},{"rate":"1–2","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1481","moleculeType":"Small molecule","molecularWeight":"490.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glimepiride is a meglitinide-class sulfonylurea that closes ATP-sensitive potassium channels in pancreatic beta cells, leading to cell depolarization and calcium influx, which triggers insulin release. This mechanism helps lower blood glucose levels in patients with type 2 diabetes by increasing endogenous insulin secretion.","oneSentence":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:38.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT03118713","phase":"PHASE4","title":"A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria","status":"TERMINATED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":33},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT02956044","phase":"PHASE1","title":"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-11","conditions":"Type2 Diabetes Mellitus","enrollment":54},{"nctId":"NCT02973477","phase":"PHASE4","title":"Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-01-12","conditions":"Type2 Diabetes, Cardiovascular Diseases","enrollment":45},{"nctId":"NCT02395237","phase":"PHASE1","title":"COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2015-05","conditions":"Healthy","enrollment":""},{"nctId":"NCT04237493","phase":"PHASE4","title":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2017-02-14","conditions":"Diabetes Mellitus, Type 2","enrollment":687},{"nctId":"NCT02312063","phase":"PHASE4","title":"Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Kansai Electric Power Hospital","startDate":"2015-02","conditions":"Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT03060980","phase":"PHASE3","title":"Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin","status":"TERMINATED","sponsor":"Intarcia Therapeutics","startDate":"2017-03-03","conditions":"Diabetes Mellitus, Type 2","enrollment":245},{"nctId":"NCT02630706","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT02226003","phase":"PHASE3","title":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-23","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01704261","phase":"PHASE3","title":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-18","conditions":"Type 2 Diabetes Mellitus","enrollment":307},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01717313","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-05","conditions":"Type 2 Diabetes Mellitus","enrollment":329},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":"Type 2 Diabetes Mellitus","enrollment":751},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT02280486","phase":"PHASE4","title":"Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":388},{"nctId":"NCT01958671","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-09","conditions":"Type 2 Diabetes Mellitus","enrollment":461},{"nctId":"NCT02954822","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-11-14","conditions":"Type2 Diabetes","enrollment":36},{"nctId":"NCT02484209","phase":"PHASE3","title":"DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)","status":"WITHDRAWN","sponsor":"Diabetes Frail Ltd","startDate":"2016-02","conditions":"Diabetes Mellitus","enrollment":""},{"nctId":"NCT01725672","phase":"PHASE1","title":"Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-09-27","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT01296412","phase":"PHASE3","title":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-11","conditions":"Diabetes Mellitus, Type 2","enrollment":653},{"nctId":"NCT01340768","phase":"PHASE3","title":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":870},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00858013","phase":"PHASE4","title":"Study of the Durability of Glycemic Control With Nateglinide","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2009-04-24","conditions":"Type 2 Diabetes Mellitus","enrollment":88},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT00701090","phase":"PHASE3","title":"A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent","enrollment":1035},{"nctId":"NCT00620282","phase":"PHASE3","title":"The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":49},{"nctId":"NCT00294723","phase":"PHASE3","title":"To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":746},{"nctId":"NCT00331851","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":584},{"nctId":"NCT00839527","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":685},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01649466","phase":"PHASE4","title":"Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":162},{"nctId":"NCT02443922","phase":"NA","title":"Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM","status":"UNKNOWN","sponsor":"Foundation for the National Institutes of Health","startDate":"2015-06","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT01890629","phase":"PHASE4","title":"Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-05","conditions":"Type 2 Diabetes Mellitus","enrollment":69},{"nctId":"NCT01459809","phase":"PHASE3","title":"Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-02","conditions":"Diabetes Mellitus, Type 2","enrollment":538},{"nctId":"NCT01075282","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":810},{"nctId":"NCT00309608","phase":"PHASE2","title":"Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Diabetes Mellitus, Type 2","enrollment":333},{"nctId":"NCT02172261","phase":"PHASE1","title":"Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-04","conditions":"Healthy","enrollment":16},{"nctId":"NCT01699932","phase":"PHASE3","title":"Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":167},{"nctId":"NCT01457911","phase":"PHASE3","title":"Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-10","conditions":"Type 2 Diabetes Mellitus","enrollment":244},{"nctId":"NCT01593137","phase":"PHASE4","title":"A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Fundación Fernández-Cruz","startDate":"2012-05","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT01768455","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-02","conditions":"Healthy","enrollment":27},{"nctId":"NCT00131664","phase":"PHASE3","title":"Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)","status":"COMPLETED","sponsor":"Canadian Heart Research Centre","startDate":"2005-09","conditions":"Type 2 Diabetes Mellitus","enrollment":391},{"nctId":"NCT01660386","phase":"PHASE4","title":"Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using \"Biphase-Hyperglycemic Clamp\"","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT00975065","phase":"PHASE4","title":"Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":266},{"nctId":"NCT01318135","phase":"PHASE2, PHASE3","title":"Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":"Type 2 Diabetes Mellitus","enrollment":576},{"nctId":"NCT00363519","phase":"PHASE3","title":"Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2006-08","conditions":"Type 2 Diabetes Mellitus","enrollment":195},{"nctId":"NCT01302158","phase":"PHASE1","title":"Drug-drug Interaction Study With ASP1941 and Glimepiride","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-12","conditions":"Healthy Subjects","enrollment":52},{"nctId":"NCT00318656","phase":"PHASE4","title":"24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Non-Insulin-Dependent Diabetes Mellitus","enrollment":23},{"nctId":"NCT00642915","phase":"PHASE4","title":"Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Diabetes Mellitus","enrollment":100},{"nctId":"NCT00576784","phase":"PHASE4","title":"Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin","status":"COMPLETED","sponsor":"IKFE Institute for Clinical Research and Development","startDate":"2005-04","conditions":"Type 2 Diabetes Mellitus, Insulin Resistance","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amaryl®","Glimy"],"phase":"phase_3","status":"active","brandName":"Open-label Glimepiride","genericName":"Open-label Glimepiride","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}